Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer.
Ontology highlight
ABSTRACT: The expression and function of caldesmon (CAD) in urothelial bladder carcinoma (BC) have not been reported. Here, we investigated the expression, prognostic value, and potential functional mechanism of CAD in primary non-muscle-invasive bladder cancer (NMIBC). Protein profiling of tissue samples using antibody microarrays showed significantly higher CAD expression in muscle-invasive BC tissues compared with NMIBC tissues. We then validated the CAD expression in BC cells by immunohistochemistry analysis using paraffin-embedded tissue blocks and western blots using BC cell lines. In addition, we examined the expression of CAD variants by reverse transcription-polymerase chain reaction, and confirmed the expression of low-molecular-weight isoforms (L-CAD), specifically encoded by WI-38 L-CAD
SUBMITTER: Lee MS
PROVIDER: S-EPMC4741901 | biostudies-literature | 2015 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA